Every publicly disclosed Cellares and Ori Biotech backer, screened: 25 confirmed, 5 pending verification

Asked:
“Can you compile a list of Cellares and Ori biotech investors?”

A public-disclosure scan for Multiply Labs Series C conflict screening: 30 company–investor pairs across two cell and gene therapy manufacturing-technology companies. Cellares shows 17 investors confirmed by company announcements or financing press releases plus 5 secondary-only names; Ori Biotech shows 8 confirmed institutional investors across its $9.4M Seed, $30M Series A and >$100M Series B.

Investor landscape by financing round

Confirmed by a company announcement or financing press release Secondary source only — verify before use Repeat across 2+ rounds — clearest conflict concern

What the map alone cannot say

Cellares' Series D closed at $257M in January 2026, then ARK Invest added $20M (to $277M) and Prime Radiant Partners added $50M, taking the round to $327M — cellares.com

Six Cellares investors appear in two or more rounds — Eclipse Ventures in three (B, C and D) — making them the clearest conflict concerns for Multiply Labs outreach — cellares.com

Bristol Myers Squibb is confirmed in Cellares' $255M Series C; any later commercial relationship outcome does not erase that historical investment disclosure — itdigest.com

On the Ori side, Amadeus Capital Partners and Delin Ventures backed all three public rounds; Novalis LifeSciences led the >$100M Series B — prnewswire.co.uk

Screening list

All confirmed names require formal conflict review before Multiply Labs outreach — not automatic exclusion. For each, check the exact fund entity, the partner involved, board-observer and information-rights status, whether the position has been sold or distributed, and whether an internal information barrier could permit investment. The five secondary-only Cellares names should be independently verified before being treated as conflicts.

Cellares — 22 names

Investor	Rounds publicly reported	Roles	Status	Source

Ori Biotech — 8 names

Investor	Rounds publicly reported	Roles	Status	Source

Public-financing disclosure scan, 30 company–investor rows compiled from company announcements, financing press releases and secondary press. It records disclosed round participation only — it is not a cap table and does not prove current ownership, board rights, information rights or active fund status. Five Cellares names rest on secondary sources only and are marked accordingly. Compiled as follow-up to the Multiply Labs Series C investor-targeting work.

This report was generated automatically by Keenable SELECT at a user's request, from publicly available web sources linked herein. Keenable does not review, verify, or endorse its contents and makes no representation as to accuracy, completeness, or timeliness; AI-based extraction may contain errors. Nothing in this report is investment, legal, financial, or other professional advice. All trademarks and referenced content remain the property of their respective owners; no affiliation or endorsement is implied. To report an error, rights concern, or request removal: legal@keenable.ai.